Milestone Pharmaceutical

Last updated: 13.02.2014

Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics based on clinically validated mechanisms. Milestone’s lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as supraventricular tachycardia and angina.


Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $17 million in venture capital financing since 2006.

At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs.

Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.


6100 Royalmount Avenue
Montreal, (Quebec)
H4P 2R2 Canada
Telephone: (514) 496-3220
Fax: (514) 496-3219



We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here